Beta-blocker tolerability in elderly heart failure patients.

[1]  M. Tendera,et al.  Treatment of chronic heart failure with carvedilol in daily practice: the SATELLITE survey experience. , 2007, International journal of cardiology.

[2]  H. Krum,et al.  Tolerability of beta‐blockers in elderly patients with chronic heart failure: The COLA II study , 2006, European journal of heart failure.

[3]  P. Poole‐Wilson,et al.  A comparison of the effects of carvedilol and metoprolol on well-being, morbidity, and mortality (the "patient journey") in patients with heart failure: a report from the Carvedilol Or Metoprolol European Trial (COMET). , 2006, Journal of the American College of Cardiology.

[4]  A. Hoes,et al.  Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. , 2005, European heart journal.

[5]  M. Packer.  Do β-blockers prolong survival in heart failure only by inhibiting the β1-receptor? A perspective on the results of the COMET trial , 2003 .

[6]  P. Poole‐Wilson,et al.  Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial , 2003, The Lancet.

[7]  P. Schnabel,et al.  Characterization of β1‐selectivity, adrenoceptor‐Gs‐protein interaction and inverse agonism of nebivolol in human myocardium , 2001, British journal of pharmacology.

[8]  K. Adams,et al.  Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. , 1996, Circulation.

[9]  P. Ridker,et al.  Age and thrombolytic therapy. , 1996, Circulation.

[10]  E. Varnauskas,et al.  Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. , 1975, British heart journal.